{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:52:54Z","timestamp":1760921574353,"version":"3.41.2"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":216,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Anakinra is a selective IL-1 inhibitor, which has been used in the context of secondary haemophagocytic lymphohistiocytosis. Although usually given in the s.c. form, previous anecdotal reports have emphasized its utility when given i.v. Our aim is to report our experience on the beneficial effects of anakinra i.v. in patients with SARS-CoV-2 and evidence of hyperinflammation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We report four patients with severe COVID-19 infection requiring intensive care admission and ventilatory support.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All four patients showed evidence of deterioration, with hyperferritinaemia and increasing oxygen requirements and with superadded bacterial infections. Upon commencement of anakinra i.v., there was subsequent improvement in the patients clinically, with reduction in ventilatory support and inotropic support, and biochemically, with rapid improvement in inflammatory markers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Anakinra is safe to use i.v. in patients with COVID-19 and evidence of superadded bacterial infection. Although its utility has not been confirmed in a randomized trial, current research in the COVID-19 pandemic aims to establish the utility of immunosuppression, including IL-1 blockade, on the outcomes of patients with moderate to severe disease. Our case series supports its use in patients with severe, life-threatening COVID-19 and evidence of hyperinflammation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkaa040","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T18:09:59Z","timestamp":1600279799000},"source":"Crossref","is-referenced-by-count":9,"title":["Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-3900","authenticated-orcid":false,"given":"Kristina E N","family":"Clark","sequence":"first","affiliation":[{"name":"Department for Rheumatology and Connective Tissue Diseases, University College London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Collas","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Royal Free Hospital London NHS Foundation Trust"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Lachmann","sequence":"additional","affiliation":[{"name":"UK National Amyloidosis Centre, University College London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Buckley","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Bhagani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"2020091613041728200_rkaa040-B1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"2020091613041728200_rkaa040-B2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/CCM.0000000000002749","article-title":"Mortality benefit of recombinant human interleukin-1 receptor antagonist for sepsis varies by initial interleukin-1 receptor antagonist plasma concentration","volume":"46","author":"Meyer","year":"2018","journal-title":"Crit Care Med"},{"key":"2020091613041728200_rkaa040-B3","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"2020091613041728200_rkaa040-B4","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2020091613041728200_rkaa040-B5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/1043-4666(92)90078-6","article-title":"Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans","volume":"4","author":"Granowitz","year":"1992","journal-title":"Cytokine"},{"key":"2020091613041728200_rkaa040-B6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-019-0309-6","article-title":"Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome","volume":"17","author":"Halyabar","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"2020091613041728200_rkaa040-B7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"2020091613041728200_rkaa040-B8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cmi.2020.04.023","article-title":"COVID-19 pandemic\u2014a focused review for clinicians","volume":"26","author":"Cevik","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2020091613041728200_rkaa040-B9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"2020091613041728200_rkaa040-B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2020091613041728200_rkaa040-B11","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2020091613041728200_rkaa040-B12","doi-asserted-by":"crossref","first-page":"108448","DOI":"10.1016\/j.clim.2020.108448","article-title":"COVID-19: immunology and treatment options","volume":"215","author":"Felsenstein","year":"2020","journal-title":"Clin Immunol"},{"key":"2020091613041728200_rkaa040-B13","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","article-title":"Pathogenic T-cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients","volume":"7","author":"Zhou","year":"2020","journal-title":"Natl Sci Rev"},{"key":"2020091613041728200_rkaa040-B14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.chom.2020.03.021","article-title":"A dynamic immune response shapes COVID-19 progression","volume":"27","author":"Ong","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2020091613041728200_rkaa040-B15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"2020091613041728200_rkaa040-B16","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2020091613041728200_rkaa040-B17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.21423","article-title":"Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis","volume":"50","author":"Allen","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2020091613041728200_rkaa040-B18","first-page":"e201834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2020091613041728200_rkaa040-B19","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"2020091613041728200_rkaa040-B20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/cts.12622","article-title":"Pharmacokinetics of anakinra in subjects of heavier vs. lighter body weights","volume":"12","author":"Yang","year":"2019","journal-title":"Clin Transl Sci"},{"key":"2020091613041728200_rkaa040-B21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","article-title":"Pharmacokinetics of anakinra in subjects with different levels of renal function","volume":"74","author":"Yang","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"2020091613041728200_rkaa040-B22","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S0140-6736(20)31057-6","article-title":"Is the HScore useful in COVID-19?","volume":"395","author":"Leverenz","year":"2020","journal-title":"Lancet"},{"author":"RECOVERY Collaborative Group","key":"2020091613041728200_rkaa040-B23"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/4\/2\/rkaa040\/33754183\/rkaa040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/4\/2\/rkaa040\/33754183\/rkaa040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T18:10:06Z","timestamp":1600279806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkaa040\/5880560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkaa040","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2020]]},"published":{"date-parts":[[2020]]},"article-number":"rkaa040"}}